About Evommune
Evommune is a company based in Sacramento (United States) founded in 2020 by Luis Pena. Evommune has raised $275.5 million across 6 funding rounds from investors including Beiersdorf, EQT and Marshall Wace. Evommune offers products and services including EVO756 and EVO301. Evommune operates in a competitive market with competitors including Aclaris Therapeutics, Incyte, Escient Pharmaceuticals, LEO Pharma and Nimbus Therapeutics, among others.
- Headquarter Sacramento, United States
- Founders Luis Pena
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Evommune, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$275.5 M (USD)
in 6 rounds
-
Latest Funding Round
$125 M (USD), Post-IPO
Feb 12, 2026
-
Investors
Beiersdorf
& 18 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Evommune
Evommune is a publicly listed company on the NYSE with ticker symbol EVMN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Evommune
Evommune offers a comprehensive portfolio of products and services, including EVO756 and EVO301.
MRGPRX2 antagonist for treating chronic spontaneous urticaria.
IL-18 targeted therapy for atopic dermatitis management.
People of Evommune
Unlock access to complete
Funding Insights of Evommune
Evommune has successfully raised a total of $275.5M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $125 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Evommune
Evommune has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Beiersdorf, EQT and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sectoral Asset Management is focused on global healthcare investment.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Multistage investments are directed toward technology, healthcare, and climate sectors.
|
Locked | Locked | Locked |
Investor details for Evommune
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Evommune
Investment portfolio details for Evommune
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Evommune
Detailed financials for Evommune
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Evommune Comparisons
Peer comparison for Evommune
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Evommune
Evommune operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Incyte, Escient Pharmaceuticals, LEO Pharma and Nimbus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of drugs for treating dermatology diseases
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
Detailed competitors of Evommune
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Evommune
Complete news archive for Evommune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Evommune
Evommune was founded in 2020.
Evommune is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Luis Pena is the current CEO of Evommune. They have also founded this company.
Evommune is a funded company, having raised a total of $275.5M across 6 funding rounds to date.
Evommune was founded in 2020 and is based in Sacramento, United States. Focus is placed on the biotechnology sector, where therapeutic candidates for chronic inflammatory disorders are developed. The pipeline includes options targeting IL-37 for rosacea and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCθ for atopic dermatitis. A tissue-based screening platform is utilized to support drug development for these conditions.
Evommune's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and LEO Pharma.
Evommune offers EVO756 and EVO301.
Yes, Evommune is publicly traded on NYSE under the ticker symbol EVMN.
Evommune has 19 investors. Key investors include Beiersdorf, EQT, Marshall Wace, RTW Investments, and RA Capital.
The ticker symbol of Evommune is EVMN on NYSE.